Adoption of adjuvant chemotherapy for non-small-cell lung cancer: A population-based outcomes study

Journal of Clinical Oncology

Volumn 28, Issue 21, 2010, Pages 3472-3478

  Booth, Christopher M ^a   Shepherd, Frances A ^a   Peng, Yingwei ^a   Darling, Gail E ^a   Li, Gavin ^a   Kong, Weidong ^a   Mackillop, William J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; ELECTRONIC MEDICAL RECORD; FEMALE; GENERAL CONDITION IMPROVEMENT; HOSPITALIZATION; HUMAN; LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ADJUVANT CHEMOTHERAPY; LUNG TUMOR; MIDDLE AGED; MORTALITY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77955292111     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.1709     Document Type: Article

References (32)

1. American Cancer Society: Cancer Facts and Figures 2008. Atlanta, GA, American Cancer Society, 2008
2. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111:1710-1717, 1997
3. Booth CM, Shepherd FA: Adjuvant chemotherapy for resected non-small cell lung cancer. J Thorac Oncol 1:180-187, 2006 (Pubitemid 47189141)
4. Booth CM, Mackillop WJ: Translating new medical therapies into societal benefit: The role of population-based outcome studies. JAMA 300: 2177-2179, 2008
5. Wen SW, Kramer MS: Uses of ecologic studies in the assessment of intended treatment effects. J Clin Epidemiol 52:7-12, 1999 (Pubitemid 29064268)
6. Conway PH, Clancy C: Comparativeeffectiveness research: Implications of the Federal Coordinating Council's report. N Engl J Med 361: 328-330, 2009
7. Stiell IG, Wells GA, Field BJ, et al: Improved out-of-hospital cardiac arrest survival through the inexpensive optimization of an existing defibrillation program: OPALS study phase II. Ontario Prehospital Advanced Life Support. JAMA 281:1175-1181, 1999 (Pubitemid 29163125)
8. Pearcey R, Miao Q, Kong W, et al: Impact of adoption of chemoradiotherapy on the outcome of cervical cancer in Ontario: Results of a population-based cohort study. J Clin Oncol 25:2383-2388, 2007 (Pubitemid 46999208)
9. Rothwell PM, Giles MF, Chandratheva A, et al: Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): A prospective population-based sequential comparison. Lancet 370:1432-1442, 2007 (Pubitemid 47576154)
10. Robles SC, Marrett LD, Clarke EA, et al: An application of capture-recapture methods to the estimation of completeness of cancer registration. J Clin Epidemiol 41:495-501, 1988
11. Clarke EA, Marrett LD, Krieger N: Cancer registration in Ontario: A computer approach, in Jenson OM, Parkin DM, MacLennan R (eds): Cancer Registration Principles and Methods. Lyon, France, International Agency for Research on Cancer, 1991, pp 246-257
12. Mackillop WJ, Zhang-Salomons J, Groome PA, et al: Socioeconomic status and cancer survival in Ontario. J Clin Oncol 15:1680-1689, 1997 (Pubitemid 27167409)
13. Williams J, Young W: A summary of studies on the quality of health care administrative databases in Canada, in Goel V, Williams JI, Anderson GM, et al (eds): Patterns of Health Care in Ontario: The ICES Practice Atlas. Ottawa, Ontario, Canada, Canadian Medical Association, 1996, pp 339-345
14. Mackillop WJ, Fu H, Quirt CF, et al: Waiting for radiotherapy in Ontario. Int J Radiat Oncol Biol Phys 30:221-228, 1994 (Pubitemid 24291133)
15. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987 (Pubitemid 17055592)
16. Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613-619, 1992
17. Evans WK, Laupacis A, Gulenchyn KY, et al: Evidence-based approach to the introduction of positron emission tomography in Ontario, Canada. J Clin Oncol 27:5607-5613, 2009
18. Arriagada R, Bergman B, Dunant A, et al: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351-360, 2004 (Pubitemid 38101630)
19. Winton T, Livingston R, Johnson D, et al: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352:2589-2597, 2005 (Pubitemid 41007845)
20. Douillard JY, Rosell R, De Lena M, et al: Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial. Lancet Oncol 7:719-727, 2006 (Pubitemid 44283661)
21. Strauss GM, Herdon MA, Maddaus DM, et al: Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol 22:621s, 2004 (suppl 14S; abstr 7019)
22. Strauss GM, Herdon JE, Maddaus MA, et al: Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol 24:365s, 2006 (suppl 18S; abstr 7007)
23. Strauss GM, Herndon JE 2nd, Maddaus MA, et al: Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 26:5043-5051, 2008
24. Alam N, Darling G, Evans WK, et al: Adjuvant chemotherapy for completely resected non-small cell lung cancer: A systematic review. Crit Rev Oncol Hematol 58:146-155, 2006
25. Pisters KM, Evans WK, Azzoli CG, et al: Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non smallcell lung cancer guideline. J Clin Oncol 25:5506-5518, 2007 (Pubitemid 350232227)
26. Kassam F, Shepherd FA, Johnston M, et al: Referral patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. J Thorac Oncol 2:39-43, 2007 (Pubitemid 47163927)
27. Younis T, Al-Fayea T, Virik K, et al: Adjuvant chemotherapy uptake in non-small cell lung cancer. J Thorac Oncol 3:1272-1278, 2008
28. Massard C, Tran Ba Loc P, Haddad V, et al: Use of adjuvant chemotherapy in non-small cell lung cancer in routine practice. J Thorac Oncol 4:1504-1510, 2009
29. Groome PA, Mackillop WJ: Uses of ecologic studies in the assessment of intended treatment effects. J Clin Epidemiol 52:903-904, 1999 (Pubitemid 29385604)
30. Earle CC, Tsai JS, Gelber RD, et al: Effectiveness of chemotherapy for advanced lung cancer in the elderly: Instrumental variable and propensity analysis. J Clin Oncol 19:1064-1070, 2001 (Pubitemid 32176282)
31. Pepe C, Hasan B, Winton TL, et al: Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol 25:1553-1561, 2007 (Pubitemid 46733082)
32. Früh M, Rolland E, Pignon JP, et al: Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected nonsmall- cell lung cancer. J Clin Oncol 26:3573-3581, 2008